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Changes in influenza viruses require regular reformu-
lation of strain-specific influenza vaccines. Vaccines based
on conserved antigens provide broader protection.
Influenza matrix protein 2 (M2) is highly conserved across
influenza A subtypes. To evaluate its efficacy as a vaccine
candidate, we vaccinated mice with M2 peptide of a widely
shared consensus sequence. This vaccination induced
antibodies that cross-reacted with divergent M2 peptide
from an H5N1 subtype. A DNA vaccine expressing full-
length consensus-sequence M2 (M2-DNA) induced M2-
specific antibody responses and protected against
challenge with lethal influenza. Mice primed with M2-DNA
and then boosted with recombinant adenovirus expressing
M2 (M2-Ad) had enhanced antibody responses that cross-
reacted with human and avian M2 sequences and pro-
duced T-cell responses. This M2 prime-boost vaccination
conferred broad protection against challenge with lethal
influenza A, including an H5N1 strain. Vaccination with M2,
with key sequences represented, may provide broad pro-
tection against influenza A.
Y
early development of influenza vaccines that are anti-
genically matched to circulating strains poses extraor-
dinary challenges. A rapidly developing pandemic would
shorten the time for strain identification and vaccine prepa-
ration; meanwhile, antigenic changes would continue.
Moreover, the need to immunize an entirely naive popula-
tion would exacerbate problems with vaccine production
and supply. 
Vaccines based on conserved antigens would not
require prediction of which strains would circulate during
an approaching season and could avoid hurried manufac-
turing in response to outbreaks. Test vaccination with
DNA constructs that express conserved influenza A nucle-
oprotein (NP) or NPplus matrix (M) induced antibody and
T-cell responses and protected against heterosubtypic
viruses (1,2). Despite the virulence and rapid kinetics of
challenge infection, DNA vaccination with NP and M
achieved limited protection against an H5N1 virus strain
isolated from the 1997 human outbreak in Hong Kong (3).
The M gene of influenza A encodes 2 proteins, both
highly conserved: M1, the capsid protein, and M2, an ion
channel protein. M2 contains a small ectodomain (4), M2e,
which makes it a target for antibody-based immunity. The
ability of anti-M2 monoclonal antibody (MAb) to reduce
viral replication (5) implicates M2, in particular M2e, as a
vaccine target. M2 vaccine candidates that have been
explored include peptide-carrier conjugates (6), bac-
ulovirus-expressed M2 (7), fusion proteins (8,9), multiple
antigenic peptides (10), and M DNAconstructs that poten-
tially express M2 (11,12). In those studies, mice were pro-
tected against challenge with homologous or
heterosubtypic viruses, but even the heterosubtypic virus-
es had an M2e sequence identical to the vaccine constructs
or differed by only 1 amino acid.
Although most human influenza viruses of H1, H2, or
H3 subtypes share identity with the M2e consensus
sequence (M2e-con) (9,13), some influenza A viruses do
not. In a study of M2e-carrier conjugate vaccines, serum
antibodies specific for M2e-con or M2e-A/PR/8/34 (H1N1)
did not cross-react with M2e peptides from H5 and H7 sub-
type avian viruses that have 3 or 4 mismatches (6). In
another study, monoclonal and polyclonal antibodies react-
ed with a subset of avian sequences (14). Although a recent
study used M2e peptide-liposome vaccines of subtypes
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prior work has documented protection against challenge
with influenza viruses in which M2e sequences differed
substantially from those of the immunizing antigen.
Priority is being given to developing vaccines that
offer broad protection against multiple influenza subtypes,
including H5N1. Indeed, development of conserved-anti-
gen vaccines, and specifically M2-based vaccines, is part
of the US Department of Health and Human Services
Pandemic Influenza Plan (www.hhs.gov/pandemicflu/
plan/). We therefore evaluated M2-based vaccine efficacy
against divergent challenge viruses. 
Methods
Mice
Female BALB/cAnNCR mice were purchased from
Division of Cancer Treatment, National Cancer Institute,
Frederick, Maryland, USA. The institutions’Animal Care
and Use Committees approved all protocols for animal
experiments.
Viruses
Influenza viruses used were A/PR/8/34 (H1N1) (3),
A/FM/1/47-MA (H1N1) (16), and A/Thailand/SP-83/2004
(H5N1) (17). Some virus stocks were propagated in the
allantoic cavity of embryonated hen eggs at 34°C for
48–72 h (A/PR/8) or 37°C for 24 h (SP-83). A/FM was
prepared as a pooled homogenate of lungs from BALB/c
mice infected 4 days previously. All experiments with
H5N1 subtypes were conducted under biosafety level 3,
enhanced containment.
Peptides and Peptide Conjugates
M2e 2–24 peptides (no NH2-terminal methionine)
were synthesized with COOH-terminal cystine residues
and conjugated to maleimide-activated keyhole limpet
hemocyanin (KLH) for vaccines. The same peptides were
also synthesized without COOH-terminal cystine and used
for antibody and T-cell assays. Influenza A NP147–155
and M2e peptides were synthesized in the core facility of
the Center for Biologics Evaluation and Research, US
Food and Drug Administration. Severe acute respiratory
syndrome (SARS) matrix peptide (209–221) was provided
by the National Institutes of Health. 
Vectors
Plasmid and recombinant adenoviral (rAd) vectors
that express B/NP and A/NP have been described (18), as
has the plasmid containing the entire M gene of A/PR/8
(2). The plasmid VR1012-M2 (termed M2-DNA above)
was generated as follows. The plasmid pCR3-M2 was
derived by PCR from the vector pCR3-M previously gen-
erated from A/PR/8 virus by reverse transcription–PCR
(19). To modify the sequence to the widely shared M2e
sequence, full-length consensus M2 cDNA with Kozak
sequence at its 5′ end was generated from 2 overlapping
M2 DNA fragments and subcloned into VR-1012,
obtained under material transfer agreement from Vical,
Inc., San Diego, CA, USA. The sequence of the M2 insert
was confirmed by restriction digestion and sequence
analysis. The replication-incompetent adenovirus that
expresses the M2 protein with the consensus sequence
(M2-Ad) was constructed by using Gateway cloning and
the ViraPower Adenoviral Expression System (both from
Invitrogen, Carlsbad, CA, USA) according to manufactur-
er’s instructions. Briefly, the M2 cDNA from VR1012-M2
was cloned by PCR into the pENTR/D-TOPO Gateway
vector and then transferred into the pAd/CMV/V5-DEST
adenoviral Gateway vector by LR Clonase (Invitrogen)
reaction to give pAd/CMV-M2. Integrity and proper inser-
tion of the cloned M2 cDNA were confirmed by sequenc-
ing. M2-Ad was generated by transfection of 293A cells
with pAd/CMV-M2. M2 expression was confirmed by
immunohistochemical staining of M2-Ad-infected Madin-
Darby canine kidney cells with M2-specific polyclonal
sera (data not shown). High-titered stocks of rAd were pre-
pared by ViraQuest, Inc. (North Liberty, IA, USA).
Adenovirus stocks were stored in 3% sucrose/phosphate-
buffered saline (PBS) at 1–2 × 1012 particles/mL and con-
firmed as negative for replication-competent adenovirus
by passage on nonpermissive cells.
Immunization 
Mice were given an intraperitoneal injection of 40 µg
peptide-KLH or unconjugated KLH in complete Freund’s
adjuvant (emulsified 1:1 with antigen in PBS). Three
weeks later, the mice were given an intraperitoneal boost-
er injection with peptide-KLH in incomplete Freund’s
adjuvant; 13 days later blood was collected. Injections
were started at 8–10 weeks of age for peptide and 6 weeks
of age for DNA. DNAvaccination at doses of 50 µg/mouse
(unless noted otherwise in a figure legend) in low-endotox-
in PBS (AccuGENE, Cambrex, East Rutherford, NJ, USA)
was given intramuscularly in the quadriceps, half to each
leg, in 3 doses 2 weeks apart. In some experiments, mice
were given a booster injection of rAd intramuscularly at a
dose of 1010 particles/mouse, 2–3 weeks after the last dose
of DNA. 
Challenge
Challenge virus in 50 µL of PBS was administered
intranasally to anesthetized mice. Isoflurane or
ketamine/xylazine was used for mice challenged with
H1N1 subtype. Reported 50% lethal dose (LD50) for H1N1
subtype was determined for 8-week-old naive BALB/c
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LD50 for the older vaccinated mice that were challenged).
Subtype H5N1 was administered intranasally to mice
anesthetized with 2,2,2-tribromoethanol in tert-amyl alco-
hol (Avertin; Aldrich Chemical Co., Milwaukee, WI,
USA). Some mice were killed so their lungs could be har-
vested; others were monitored for body weight and death.
Monitoring continued until all animals died or were recov-
ering, as indicated by body weight. 
In Vivo T-Cell Depletion
Acute depletion of lymphocyte populations by MAb
treatment on days –3, +2, +8 relative to day of challenge
was performed as described previously (18) and used
MAbs GK1.5, specific for mouse CD4; 2.43, specific for
mouse CD8; and SFR3-DR5, specific for a human leuko-
cyte antigen as a negative control. Splenocytes were ana-
lyzed 2 days after challenge (before the next injection) by
flow cytometry to confirm completeness of in vivo T-cell
depletion, as described (2).
ELISA
ELISA for M2-specific antibodies was performed on
plates coated with 15 µg/mL of synthetic peptides in 0.007
mol/L borate buffer and 0.025 mol/L saline; the rest of the
procedure was as described (20).
Passive Serum Transfer
Naive mice were given intraperitoneal injections of
pooled serum, 1 mL per mouse, from mice immunized
with M2-DNA plus matched Ad booster or from control
mice (B/NP-DNA, M2-H5[HK] peptide-KLH conjugate,
or A/PR/8 virus). Mice were challenged with a moderate
dose of A/PR/8 virus the day after serum transfer; antibody
levels in recipients were not measured.
Spleen Cell Fractionation
T cells were enriched by negative selection that used
magnetic beads. Briefly, splenocytes were depleted of ery-
throcytes and labeled with biotinylated antimouse B220,
CD11b, and PanNK antibodies (BD Pharmingen, San
Diego, CA, USA). After labeling, cells were incubated
with Streptavidin MicroBeads (Miltenyi Biotec, Auburn,
CA, USA). Unlabeled T cells and labeled non–T cells were
separated through the Miltenyi AutoMACS system accord-
ing to the manufacturer’s instructions.
Enzyme-linked Immunosorbent Spot (ELISPOT) Assay
This assay detected T-cell responses to M2 peptides.
ELISPOT IP plates (Millipore; Billerica, MA, USA) were
coated with 50 µL of Hank’s balanced salt solution
(Hyclone, Logan, UT, USA) containing 5 µg/mL of
anti–interferon-γ (IFN-γ) MAb AN18 (BD Pharmingen)
and incubated overnight at 4°C. The membrane was
washed and then blocked with medium containing 10%
fetal bovine serum for 60–90 min at room temperature.
Splenocytes depleted of erythrocytes were added to wells
in 2-fold dilutions, starting at 250,000 cells/well in 50 µL.
Peptides (SARS-M-209–221, NP147–155 of A/PR/8, or
M2–2-24 of A/PR/8) were added at a final concentration of
1 µg/mL. After incubation for 36–48 h at 37°C, bound
IFN-γ was detected with 50 µL of biotinylated MAb
R4–6A2 (BD Pharmingen) at 1 µg/mL. Spots were devel-
oped by using alkaline phosphatase–labeled streptavidin
and 5-bromo, 4-chloro, 3-indolylphosphate/nitroblue tetra-
zolium substrate (Kirkegaard and Perry Laboratories,
Gaithersburg, MD, USA) and counted with an ELISPOT
reader (Zeiss; Thornwood, NY, USA). 
Virus Quantitation
Lungs were homogenized in 1 mLof sterile PBS, clar-
ified by centrifugation, and titrated for virus infectivity by
50% egg infectious dose (EID50) assay as described (3).
The limit of virus detection is 1.2 log10 EID50/mL.
Challenge virus stocks were titrated on Madin-Darby
canine kidney cells as described previously (18).
Statistical Analysis
The serologic assays and detection of M2-specific T
cells were performed multiple times with comparable
results. Some vaccinations were repeated with independent
groups (as noted in the figure legends); those performed
once used numbers of animals per group adequate for sta-
tistical significance. Lung virus titers were compared by
using 1-way analysis of variance on log-transformed data,
followed by pairwise multiple comparison (Holm-Sidak
method). Weight loss after challenge was compared for sur-
vivors on each day by also using 1-way analysis of variance
followed by pairwise multiple comparison (Holm-Sidak).
This method overestimates body weight in groups with
deaths because the animals that died would have had very
low body weights, affecting the average, especially in the
negative control groups. Nonetheless, differences between
vaccinated groups were significant in the instances stated.
Comparison of cumulative survival rates used the log-rank
test, followed by pairwise multiple comparison, again by
using the Holm-Sidak method. Overall significance level
for Holm-Sidak tests was p = 0.05. All statistical analyses
were performed with SigmaStat Software v3.11 (Systat
Software, Point Richmond, CA, USA).
Results
M2e-KLH Vaccination 
For proof-of-concept studies, peptides representing
M2e-con (9) and additional viral M2 ectodomains (Table)
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mice. Immune serum samples were analyzed for M2-spe-
cific antibodies by ELISA on plates coated with synthetic
M2e peptides with sequences from 2 viruses of H1N1 and
2 of H5N1 subtype. Serum from KLH-immune mice did
not react with any of the peptides, but each M2e-immune
serum sample reacted with M2e-PR8, M2e-FM, and M2e-
H5(SP-83) peptides (Figure 1A–C). Cross-reactions were
lower on the M2e-H5(HK) peptide (Figure 1D). 
M2e-vaccinated mice were then challenged with either
A/PR/8 or A/FM and monitored for weight loss (as a meas-
ure of illness) and death. Weight losses were consistent
with a hierarchy of protection based on sequence similarity
(data not shown), and differences from control mice were
statistically significant. In the same groups, 100% of mice
vaccinated with M2e-con or M2e-FM survived challenge
with A/PR/8 and A/FM, but  M2e-H5(HK)/KLH vaccina-
tion provided incomplete protection (Figure 2A and B). 
M2-DNA Vaccination
To investigate whether, like M2e peptide, DNAvacci-
nation could protect against viruses with quite divergent
M2e sequence, we tested M- and M2-DNA for efficacy.
M-DNA with the A/PR/8 sequence protected against chal-
lenge with A/PR/8 (Figure 3A). M2-DNAwith the consen-
sus sequence also protected against this A/PR8 challenge;
however, M1-DNA did not (data not shown). For chal-
lenge with A/FM, M2-DNA was more efficacious than M-
DNA (Figure 3B).
M2-DNA Vaccination Followed by M2-Ad Boost
Previously, we have shown for NP vaccination that
boosting with rAd induces more potent antibody and T-cell
(especially CD8+) responses than does DNA vaccination
alone and can protect against challenge with highly patho-
genic H5N1 subtype (18). We investigated whether boost-
ing with rAd would also enhance immunity to M2. The
A/M2 gene with the consensus sequence was cloned into a
replication-deficient Ad construct (M2-Ad). Mice were
primed with DNA as before and boosted with M2-Ad or
control B/NP-Ad. Two weeks later, serum samples were
collected and assayed for M2-specific immunoglobulin
(Ig) G by ELISA on peptides as above (Figure 4A–D).
Mice given the booster of M2-DNA+M2-Ad had dramati-
cally greater M2e-PR8–specific IgG antibody responses
than mice given either component alone (M2-DNA+B/NP-
Ad or B/NP-DNA+M2-Ad; Figure 4A). Moreover, IgG
cross-reactivity with M2e-FM (3 amino acid differences;
Figure 4B) and M2e-H5(SP-83) (3 amino acid differences;
Figure 4C) was found with serum from mice given M2-
Ad; cross-reactivity was even greater with serum from
mice given M2-DNA+M2-Ad. These serum samples,
however, did not cross-react with M2e-H5(HK) (4 amino
acid differences; Figure 4D), although serum from mice
immunized with M2e-H5(HK)-KLH as positive controls
reacted strongly (data not shown).
Protective immunity due to vaccination with M2-
DNA+M2-Ad was tested by challenge with A/PR/8 (high-
dose) or A/FM (moderate dose) virus. Of mice vaccinated
with M2-DNA+M2-Ad, 100% survived challenge with
A/PR/8 and A/FM virus; of mice vaccinated with B/NP-
DNA+B/NP-Ad, 20% survived challenge with A/PR/8 and
none survived challenge with A/FM (Figure 5A,B). Thus,
the prime-boost vaccination protected against challenge
viruses in which M2e sequences were similar to or diver-
gent from those of the vaccine.
T-cell Response 
T-cell responses to M2 have been observed (7).
Immunization with cDNA expressing full-length M2 pro-
tein might induce, in addition to antibody, M2-specific T-
cell responses not induced by peptides. To address the
contribution of T-cell responses, we immunized mice to
M2 by prime-boost and acutely depleted them of T cells
just before and during the challenge period. Lymphocyte
depletion was confirmed to be complete; residual splenic
CD4+ or CD8+ cells were <1% (data not shown). Of the
B/NP control mice, 100% died of A/PR/8 infection by day
8 after challenge, while 100% of M2-immune mice treated
with a control MAb (SFR) survived (Figure 6A).
Individual depletion of CD4+ or CD8+ T cells did not abro-
gate protection. Depletion of CD4+ and CD8+ T cells
together partially, but statistically significantly, abrogated
M2-induced protection (Figure 6A) but left some protec-
tion significantly different from that in the B/NP control
mice. Thus, under these challenge conditions, T cells are
important. M2e-specific immunity has been reported to be
natural killer (NK)-cell dependent (21). We found that
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were protected similarly to controls (data not shown).
Thus, while NK cells may play a role, they were not
required under the conditions we studied. 
Given the effect of T-cell depletion, we tested for in
vitro M2-specific IFN-γ–producing T cells. The IFN-γ
ELISPOT assay showed positive responses to an amino-
terminal M2 peptide in spleen cells from mice immune to
M2-DNA+M2-Ad (Figure 6B) and to A/PR/8 (data not
shown). After spleen cells were fractionated by magnetic
bead separation (see Methods), the non–T-cell fraction did
not respond, while the unfractionated cells and T-cell frac-
tion maintained a strong M2-specifc IFN-γ response
(Figure 6B).
Role of M2-specific Antibody 
On the basis of information from previous studies (see
Discussion), we tested the ability of antibodies induced by
DNA prime–Ad boost to passively transfer protection. All
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Figure 1. Results of matrix protein 2 (M2)e–keyhole limpet hemo-
cyanin (KLH) vaccination, showing induction of cross-reactive anti-
body responses. Mice (7–9 per group) were immunized
intraperitoneally with KLH or M2e peptides conjugated to KLH
(M2e-con/KLH, M2e-FM/KLH, or M2e-H5(HK)/KLH) in complete
Freund’s adjuvant. After 21 days, the mice were given an intraperi-
toneal booster with KLH or M2e-peptide/KLH in incomplete
Freund’s adjuvant. Immune serum was collected 13 days after
booster and assayed for immunoglobulin (Ig) G reactive to various
M2e peptides by ELISA. Plates were coated with M2e-PR8 (panel
A), M2e-FM (panel B), M2e-H5(SP-83) (panel C), or M2e-H5(HK)
(panel D). Data are representative of multiple experiments. OD,
optical density; e, ectodomain.
Figure 2. Results of matrix protein 2 (M2)e–keyhole limpet hemo-
cyanin (KLH) vaccination, showing cross-protection. Mice (7–9 per
group) were vaccinated as in Figure 1. Six weeks after the boost-
er, they were anesthetized with isoflurane and challenged with 10x
the 50% lethal dose (LD50) of A/PR/8 (A) or A/FM (B) viruses and
then monitored for survival. Cumulative survival rates after chal-
lenge with A/PR/8 or A/FM virus differed significantly from those of
KLH controls for all M2e-conjugates (p = 0.001 and p<0.001,
respectively, log rank). e, ectodomain.(100%) mice given serum from M2-immune or A/PR/8-
infected mice survived, while only 50% given control
B/NP-immune serum survived (Figure 6C; p<0.001, log
rank). Passive serum antibody from M2 prime–boost
immune mice also conferred significant protection against
weight loss (Figure 6D).
Heterologous Challenge, Including SP-83 (H5N1)
Because protection against challenge with A/FM virus
that has an M2e sequence quite divergent from that of the
immunizing sequence was encouraging, we tested whether
M2-DNA+M2-Ad vaccination could protect against chal-
lenge with H5N1 subtype. Mice were immunized 3× with
B/NP-DNA (negative control), A/NP-DNA (positive con-
trol), or consensus M2-DNA, and boosted with matched
rAd. Mice were challenged with a lethal dose of
A/Thailand/SP-83/2004 (H5N1) virus in which M2e dif-
fered from the consensus by 3 amino acids. On day 5 after
infection, a random subset of animals was killed and their
Matrix Protein 2 Vaccination
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Figure 3. Results of matrix protein 2 (M2)–DNA vaccination, show-
ing protection against divergent influenza viruses. Mice (8–10 per
group) were vaccinated with DNA as described in Methods except
at a dose of 100 µg/mouse. Approximately 2 weeks after the last
dose of DNA, mice were challenged with 7× the 50% lethal dose
(LD50) of virus and monitored for survival. A) A/PR/8 challenge:
Cumulative survival rate of mice vaccinated with M-DNA or M2-
DNA was significantly higher than that of mice vaccinated with
B/NP-DNA (p<0.001, log rank). B) A/FM challenge: Cumulative
survival rate differed significantly among groups (p = 0.041, log-
rank), although in post hoc Holm-Sidak tests, pairs did not differ
significantly (p>0.05).
Figure 4. Results of matrix protein 2 (M2) vaccination and booster
with DNA prime–adenovirus (Ad), showing cross-reactive antibod-
ies. Mice (8–10 per group) were vaccinated with DNAand given an
Ad booster as described in Methods. Immune serum collected 3
weeks after the booster was assayed for immunoglobulin (Ig) G
reactive to various M2e peptides by ELISA, as described in
Methods. Plates were coated with M2e-PR8 (panel A), M2e-FM
(panel B), M2e-H5(SP-83) (panel C), or M2e-H5(HK) (panel D).
OD, optical density.  e, ectodomain.lung virus titers were measured. Virus titers of mice vacci-
nated with A/NP or with M2 were significantly reduced
compared with those of control mice (Figure 7A). The
remaining mice were monitored for weight loss and sur-
vival. Weight loss was less in mice vaccinated with A/NP
and M2 than in control mice (Figure 7B). All the B/NP-
immune mice died of SP-83 infection by day 11 postchal-
lenge. All (100%) A/NP-immune mice and all but 1
M2-immune mouse survived (Figure 7C). 
Discussion 
Our results indicate that M2 vaccination can induce
cross-reactive antibody responses, virus-specific T-cell
responses, and protection against challenge with lethal het-
erologous virus. As has been found in previous studies of
M2-based vaccines, we found strong antibody responses to
the conserved M2e region. Anti-M2 antibodies in the
serum of mice immunized with M DNA suggest expres-
sion of M2 from this plasmid (not shown). However, reac-
tivity could be due to the 9 amino acid portion shared with
the M1 sequence, and we did not explore this possibility.
Fan et al. used A/PR/8 and Aichi M2e-carrier conjugates
for immunization, and the resulting antibodies did not
cross-react with the avian M2e sequences tested (6). We
found cross-reactivity with M2e peptides that had consid-
erable sequence divergence from the human influenza M2
consensus. Immunization with M2e-con/KLH induced
antibodies that were reactive with M2e-H5(SP-83) peptide
but less reactive with M2e-H5(HK).  However, immuniza-
tion with M2e-H5(HK)/KLH induced antibodies that were
reactive with all the M2e peptides. This pattern parallels
the results of Liu et al. (14). However, neither Fan et al. nor
Liu et al. investigated protection against challenge with
H5N1 subtype.
In our lethal challenge studies, M2e peptide conju-
gates protected against not only a 1934 subtype H1N1
virus (A/PR/8) but also a 1947 subtype H1N1 virus
(A/FM). The latter virus, which is virulent in mice, has an
M2e sequence with 3 amino acid differences from the con-
sensus and thus is as divergent from the consensus
sequence as some M2-H5 sequences. Encouraged by this
broad cross-reactivity and cross-protection, we expanded
the study to DNA vaccination and DNA prime–Ad boost
regimens. These approaches have the advantage of provid-
ing more epitopes than peptide immunization and relevant
T-cell immunity. 
Using M2 consensus DNA vaccination with or with-
out Ad boost, we again saw cross-reactivity on avian pep-
tides M2e-H5(SP-83) and M2e-H5(HK), although
cross-reactivity was low on the HK peptide. T-cell
responses to M2 peptides were detected by ELISPOT. 
Several studies have shown that M2e-specific anti-
bodies can mediate protection against influenza infection
in vivo (9,10,13). In agreement with those studies, we
found that serum antibodies induced by peptide conjugates
or by prime-boost vaccination could transfer protection to
naive recipients. We found that T cells were also important
because depletion of CD4+ and CD8+ T cells during the
challenge period reduced protection against a higher chal-
lenge dose. This could reflect M2e-specific memory T
cells, which we have demonstrated in spleen and peripher-
al blood by ELISPOT, or a concurrent T-cell response to
challenge virus supplementing the protective effects of
antibodies. 
In lethal challenge studies, the M2 consensus DNA
and rAd constructs could protect against not only A/PR/8
but also against A/FM, a virus quite divergent in the M2e
sequence. Furthermore, they could protect mice against
challenge with SP-83 (H5N1) isolated from a fatal human
case, at a dose lethal to control mice. Virus replication in
lungs and illness reflected by loss of body weight were
also reduced by M2 immunization. Protection against chal-
lenge with other H5N1 subtypes remains to be explored,
and serologic results on M2e-H5(HK) peptide suggest
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Figure 5. Results of vaccination and booster with DNA prime–ade-
novirus (Ad), showing cross-protection. Mice (8–10 per group)
were immunized as in Figure 4 or intranasally given a sublethal
priming infection with A/PR/8. Three weeks later they were chal-
lenged with a high dose of A/PR/8 (1.5 × 104 50% lethal dose
[LD50]) (A) or moderate dose of A/FM (10 LD50) (B) and monitored
for survival. The cumulative survival rate for mice immunized with
A/PR/8 and M2-DNA+M2-Ad was significantly higher than that for
mice immunized with B/NP-DNA+B/NP-Ad (p<0.001, log rank).
Data are representative of multiple experiments.results of such studies might differ on the basis of
sequence variations. 
M2 expression constructs with various M2e sequences
could be used as vaccines. Our observation of protection
across substantial sequence divergence means that H5-
derived vaccines might also protect against circulating
H1N1 and H3N2 subtypes. An additional advantage of
protection across substantial divergence is potential pro-
tection by an M2 vaccine against an unexpected subtype
that could cause a pandemic.
One concern about M2 vaccines is the possibility of
escape mutants. A study of forced escape mutants found
limited diversity (13), which indicates that structural con-
straints, perhaps due to requirements of the M1 structure
encoded by the same segment, may limit drift.
The cross-reactivity and protective efficacy of M2-
specific antibodies suggest that M2-specific MAbs could
be useful for antiviral therapy. These features, combined
with constraints on M2 structure, highlight the potential of
M2-specific MAbs to inhibit replication of influenza virus-
es, including some H5N1 strains. Although traditional M2-
directed drugs (e.g., amantadine) have led to drug
resistance, the mutations that confer resistance are within
the transmembrane region (22), which may have fewer
structural constraints than the ectodomain. 
An M2 prime-boost regimen is intended to be com-
bined with vaccination against additional antigens rather
than acting as a standalone vaccine. For example, prime-
boost vaccination against conserved NP is highly protec-
tive ([18]; Figure 7). The use of multiple antigens has
several advantages: reduced likelihood of escape mutants,
better coverage of human leukocyte antigen haplotypes in
the genetically diverse human population, and a broader
spectrum of immune response mechanisms (with antibod-
ies perhaps dominating for M2 and cytotoxic T lympho-
cytes for NP).
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Figure 6. Role of T- and B-cell immunity in matrix protein 2 (M2)–specific protective immunity. A) Mice (9 per group) were immunized with
M2-DNAor B/NP-DNAand boosted with matched adenovirus (Ad) as described in Methods. Three weeks after Ad boost, M2-DNAgroups
were acutely depleted of T cells with monoclonal antibodies (MAbs) to CD4+ or CD8+ or both, or given control MAb SFR3-DR5, as
described in Methods. Mice were challenged with 1.5 × 104 50% lethal doses (LD50) of A/PR/8. Compared with the cumulative survival
rate for the SFR control, survival rates differed significantly for mice depleted of both T-cell subsets (p<0.001, log-rank), although some
protection remained, which differed significantly from that of the B/NP control (p<0.001, log-rank). B) Mice were immunized with M2-
DNA+M2-Ad as described under A. Five months after mice received the Ad boost, spleen cells were isolated and pooled from immune
mice (n = 10), fractionated into T-cell and non–T-cell populations, and assayed for interferon-γ (IFN- γ)–producing cells by enzyme-linked
immunosorbent spot assay, as described in Methods. C and D) Serum collected from immune mice was passively transferred intraperi-
toneally into naive BALB/c mice (8 per group). The recipients were challenged with 10 LD50 of A/PR/8 and monitored for survival (C) and
weight loss (D). The cumulative survival rate for mice given A/PR/8 immune serum, M2-DNA+M2-Ad-immune serum, or M2e-
H5(HK)/keyhole limpet hemocyanin–immune serum was significantly higher than that for mice given B/NP-DNA+B/NP-Ad–immune
serum (p<0.001, log rank). For weight loss, M2 prime-boost differed from B/NP prime-boost at days 8, 10, and 13 (p<0.003, analysis of
variance; p<0.05, Holm-Sidak pairwise multiple comparison). SARS, severe acute respiratory syndrome; IFN- γ, interferon- γ. Vaccines based on conserved antigens are not intend-
ed to replace strain-matched vaccines that induce neutral-
izing antibodies and thus prevent infection. However,
strain-matched vaccines may be difficult to produce in
adequate quantities in short time periods, and continued
antigenic drift may render them ineffective. Vaccinations
as described here, based on M2, might reduce deaths and
severity of disease while strain-matched vaccines were
being prepared and could enhance protection afforded by
inactivated vaccines. Immunogenicity and safety studies in
people are needed to evaluate this approach.
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